Headline Risks Affecting Healthcare Tech & Distribution Sector Will Likely Continue in 2025: BofA Analyst
Headline Risks Affecting Healthcare Tech & Distribution Sector Will Likely Continue in 2025: BofA Analyst
Potential policy shifts under the next administration could involve adjustments to the Inflation Reduction Act, expanded access to health savings accounts (HSAs), and increased support for fertility benefits.BofA Securities predicts that headline risks affecting the Healthcare Tech & Distribution sector in 2024 will likely continue in 2025.
美银证券预测，影响医疗科技与药品经销板块的风险将在2024年持续，并可能在2025年继续存在。
Key areas of concern include pharmacy benefit managers (PBMs), retail pharmacies, distributors, fertility benefits, and direct-to-consumer (D2C) pharmacies.
主要关注领域包括药房福利管理者（PBMs）、零售药房、分销商、生育福利和直接面向消费者（D2C）药房。
While regulatory pressure on PBMs is expected to persist, the analyst believes this will mainly impact profit margins and growth rates rather than lead to major changes in the business model.
尽管预计对PBMs的监管压力将持续，但分析师认为这主要会影响利润率和增长率，而不是导致业务模式的重大变化。
Potential policy shifts under the next administration could involve adjustments to the Inflation Reduction Act, expanded access to health savings accounts (HSAs), and increased support for fertility benefits.
下一届政府可能进行的政策调整可能包括对《通货膨胀削减法》的调整、扩大健康储蓄账户（HSAs）的访问权限，以及增强对生育福利的支持。
BofA upgraded Cardinal Health Inc. (NYSE:CAH) from Neutral to Buy. The analyst notes Cardinal Health's core pharmaceutical segment is growing faster than its competitors, with this trend expected to strengthen in the coming year.
美银将卡地纳健康公司（NYSE:CAH）从中立评级上调至买入。分析师指出，卡地纳健康的核心药品板块增长速度快于其竞争对手，预计这一趋势将在来年进一步增强。
Also Raed: Cardinal Health Raises 2025 Profit Outlook Again, Helped By Strong Drug Distribution Business
另据报道：卡地纳健康再次上调2025年利润预期，受到强劲药品经销业务的支持。
The company is benefiting from a unique advantage in its pharmacy benefit management (PBM) business, which could add 2-3 percentage points to earnings per share growth through fiscal 2026.
该公司在其药房福利管理（PBM）业务中享有独特优势，这可能在到2026财年为每股收益增长增加2-3个百分点。
Despite its stronger growth potential, Cardinal's stock is trading at a notable discount compared to McKesson Corporation (NYSE:MCK), but this gap is likely to close or reverse within the next year.
尽管卡地纳健康的增长潜力更强，但与麦克森公司（NYSE:MCK）相比，其股票的交易价格显著折扣，但这一差距可能在明年内缩小或反转。
BofA has also upgraded Henry Schein (NASDAQ:HSIC) from Underperform to Buy and raised the price target from $69 to $84, recognizing it as a top-tier dental business poised for long-term earnings growth.
美国银行已将汉瑞祥（纳斯达克:HSIC）评级从跑输大盘上调至买入，并将目标价从69美元上调至84美元，认为其是一个有潜力的顶级牙科业务，能够实现长期盈利增长。
The company is recovering from last year's cybersecurity incident, which should boost reported figures.
公司正在从去年的网络安全事件中恢复，这将提升报告数字。
With these challenges behind it and expectations now more realistic, the analyst writes Henry Schein offers a strong opportunity to benefit from a recovering dental market.
在这些挑战解决后，分析师认为汉瑞祥提供了一个强有力的机会，可以从复苏的牙科市场中受益。
The company could see additional upside in the medium to long term, driven by a shift toward private-label products and a growing focus on specialty services. The analyst notes the price target of $84 is reasonable given its position at a market low.
公司可能在中长期内看到额外的上行潜力，这得益于向私有品牌产品的转变以及对特殊服务日益增长的关注。分析师指出，84美元的目标价在市场低位时是合理的。
Price Action: At the last check Tuesday, CAH stock was up 0.61% at $120.36, and HSIC stock was down 0.08% at $71.70.
价格走势：根据周二最后一次检查，卡地纳健康（CAH）股票上涨0.61%，报120.36美元，汉瑞祥（HSIC）股票下跌0.08%，报71.70美元。
- Phillips 66 Powers Up With $2.2 Billion Deal For EPIC Y-Grade's NGL Business
- Phillips 66 以22亿交易收购 EPIC Y-Grade 的 NGL 业务
Photo by Casimiro PT via Shutterstock
照片由Shutterstock提供
